trending Market Intelligence /marketintelligence/en/news-insights/trending/ZlsnMM25ZkHPWSEfmQDfRA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Bristol-Myers highlights gains to shareholders ahead of vote for Celgene deal

StreetTalk – Episode 70: Banks' Liquidity Conundrum Could Fuel M&A Activity

Street Talk Episode 70 - Banks' Liquidity Conundrum Could Fuel M&A Activity

StreetTalk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk – Episode 69: Banks left with pockets full of cash and few places to go


Bristol-Myers highlights gains to shareholders ahead of vote for Celgene deal

The Bristol-Myers Squibb Co. board continues to ask its shareholders to vote in favor of the company's $95 billion acquisition of Celgene Corp. ahead of an April 12 meeting.

New York-based Bristol-Myers said the transaction, which has seen opposition from certain shareholders, will allow it to buy the "whole necklace" rather than stringing together individual assets. The deal takes into account long-term growth for the company and will eliminate paying potentially high individual premiums and minimize risks related to smaller transactions.

In a letter, Bristol-Myers' board said the combined company will be propelled to the top spot in the oncology and cardiovascular segments. The transaction will bring together nine blockbuster products with more than $1 billion in annual sales each. The companies also said they have a strong product pipeline of early and late-stage assets.

Bristol-Myers said it had undertaken conservative forecasts for Celgene's cancer drug Revlimid but was confident after the U.S. Patent and Trademark Office's favorable decision related to the medicine.

Wellington Management Group LLP, Bristol-Myers' largest investor, and Starboard Value LP, which holds a much smaller share at 0.06%, have opposed the proposed deal. Both investors cited the patent cliff threatening Celgene's leading cancer drug Revlimid. The investors believe the transaction will eat into Bristol-Myers' revenue in the future.

Celgene had several pipeline drugs stumble in the development process. Earlier in March, Celgene's cancer drug Abraxane failed a late-stage study to treat pancreatic cancer while multiple sclerosis therapy ozanimod saw a rejection by the U.S. Food and Drug Administration in February 2018. Its experimental Crohn's disease drug GED-0301 failed in a late-stage study in 2017. The company had spent about $710 million to acquire the drug.

Earlier in January, two members of Congress had also raised concerns about the deal's impact on competition.

Bristol-Myers, however, noted in its letter that the deal will generate cost savings of about $2.5 billion and that it also plans to undertake a $5 billion share buyback program, subject to the closing of the transaction, market conditions and board approval.

Bristol-Myers CEO Giovanni Caforio has already dismissed speculation that the pharmaceutical giant could become an acquisition target.